financetom
Business
financetom
/
Business
/
US to seek rival bids for Artemis 3 moon landing as SpaceX lags, NASA chief says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US to seek rival bids for Artemis 3 moon landing as SpaceX lags, NASA chief says
Oct 20, 2025 9:32 AM

*

NASA chief says US must return to moon before China lands

there

*

Artemis 2 on track, may launch earlier than planned

*

NASA chief Duffy suggests Blue Origin, others may join

bidding

By Joey Roulette

WASHINGTON, Oct 20 (Reuters) -

NASA's top official on Monday said the U.S. space agency was

opening up the contract for its Artemis 3 astronaut moon landing

to compete against billionaire Elon Musk's SpaceX, the mission's

current contractor, which was running behind schedule.

"I'm in the process of opening that contract up. I think

we'll see companies like Blue get involved, and maybe others,"

NASA administrator Sean Duffy, who also serves as U.S.

Transportation Secretary, told Fox News' "Fox & Friends"

program.

Blue Origin is a SpaceX rival founded by billionaire Jeff Bezos,

former president and CEO of Amazon.com.

"We're going to have a space race in regard to American

companies competing to see who can actually get us back to the

moon first."

Since 2021, SpaceX has had a NASA contract, now worth $4.4

billion, to land humans on the moon by 2027 using its

Starship rocket

. The increasingly delayed target date is mostly aimed at

beating China's 2030 moon landing goal. The mission would be the

first human lunar landing since Apollo 17 in 1972.

Blue Origin, with its Blue Moon lander,

has a similar lunar landing contract

awarded by NASA in 2023 but for later Artemis missions. The

company had fought for years for that contract, pushing NASA and

lawmakers to select a second lander for redundancy.

Duffy's remarks on Monday suggest Blue Origin could soon

compete to snatch the Artemis 3 mission from SpaceX, whose

delayed Starship has raised concerns among agency officials in

recent months.

NASA did not immediately return requests for comment and

specifics on Duffy's remarks.

NASA's multibillion-dollar Artemis program is a series of

missions involving multiple contractors aimed at returning

humans to the moon for a long-term presence there. Artemis 3 has

been planned for 2027 with SpaceX's Starship.

But Duffy said Musk's SpaceX was not on schedule and could put

the U.S. behind its rival, with President Donald Trump wanting

to see the mission take place before his White House term ends

in January 2029.

"They're behind schedule, and so the president wants to make

sure we beat the Chinese," Duffy told Fox.

Artemis 2, a 10-day flight around the moon and back

involving systems built by Boeing ( BA ), Northrop Grumman ( NOC )

and Lockheed Martin ( LMT ), is on track for April and

could get moved up to February, he added.

Bezos and Blue Origin CEO Dave Limp reportedly spoke with Trump

over the summer when the Republican president was feuding with

Musk, who backed Trump in the 2024 election and went on to lead

the broad effort to cut the federal government known as DOGE.

Representatives for SpaceX and Blue Origin could not immediately

be reached for comment.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Netflix Unusual Options Activity For December 09
Netflix Unusual Options Activity For December 09
Dec 9, 2024
Investors with a lot of money to spend have taken a bearish stance on Netflix ( NFLX ) . And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big...
Editas Medicine Shares Jump as Potential Gene Therapy for Sickle Cell Disease Found to Be 'Well-Tolerated'
Editas Medicine Shares Jump as Potential Gene Therapy for Sickle Cell Disease Found to Be 'Well-Tolerated'
Dec 9, 2024
12:25 PM EST, 12/09/2024 (MT Newswires) -- Editas Medicine ( EDIT ) shares were up almost 7% in recent trading Monday after the company said that its renizgamglogene autogedtemcel, or reni-cel, therapy continued to be well-tolerated in sickle cell disease patients. Updated data from the company's clinical trial showed that all 28 subjects with severe sickle cell disease showed a...
Update: Nippon Steel Tries to Garner US Steel Workers' Support by Detailing Capital Expenditure Plans of 'At Least' $2.7 Billion
Update: Nippon Steel Tries to Garner US Steel Workers' Support by Detailing Capital Expenditure Plans of 'At Least' $2.7 Billion
Dec 9, 2024
12:24 PM EST, 12/09/2024 (MT Newswires) -- (Update with United Steelworkers' response to a request for comment.) Nippon Steel sent a letter addressed to US Steel employees, detailing plans to spend 'at least' $2.7 billion in capital expenditures on United Steelworkers-represented facilities, to garner support for its planned acquisition of US Steel. We had hoped that continued discussions with the...
Trump aides contact Google, Meta, Snap over online drug sales, The Information reports
Trump aides contact Google, Meta, Snap over online drug sales, The Information reports
Dec 9, 2024
(Reuters) -President-elect Donald Trump's transition team has invited five major tech companies, including Google, Microsoft and Meta Platforms to a meeting in mid-December about dealing with online sales of drugs, The Information reported on Sunday. A representative for Jim Carroll, the drug czar during Trump's first term, and Trump's transition team emailed staffers from the three tech giants on Thursday,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved